Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

282 trials

NCT06617325
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Phase 3 · United Arab Emirates, Argentina, Belgium, Canada, Chile, China, Germany, Denmark, Spain, France, United Kingdom, Greece, Italy, Japan, South Korea, Mexico, Netherlands, Peru, Poland, Puerto Rico, Serbia, Taiwan, United States · 253 sites
Registry update: 2 Nov 2026
2024-518580-35-00
Recruiting
Steroid withdrawal in SLE
Phase 4 · Italy · 5 sites
Registry update: 19 Nov 2025
NCT06642402
Recruiting
Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles
Not applicable · Denmark · 4 sites
Registry update: 9 Sept 2025
NCT06888960
Recruiting
Safety Study of CC312 in Autoimmune Disease Patients
Early phase 1 · China · 1 site
Registry update: 17 Sept 2025
NCT06691152
Recruiting
Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus
Phase 1 · China · 1 site
Registry update: 15 Nov 2024
NCT06379646
Recruiting
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Not applicable · China · 1 site
Registry update: 22 Oct 2026
NCT06314282
Recruiting
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Not applicable · Argentina, China, Costa Rica, Egypt, Guatemala, Kuwait, Kazakhstan, Mexico, Oman, Qatar, Saudi Arabia, Taiwan · 29 sites
Registry update: 1 Sept 2026
NCT06585514
Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Phase 1/2 · China · 1 site
Registry update: 10 Mar 2026
NCT06535412
Recruiting
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
Phase 1/2 · China · 1 site
Registry update: 29 Jun 2026
NCT06675422
Recruiting
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Phase 1/2 · China · 1 site
Registry update: 5 Nov 2024
NCT06527872
Recruiting
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
Not applicable · France, Italy, Japan, United States · 7 sites
Registry update: 2 Jul 2026
NCT06625671
Recruiting
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
Phase 1/2 · Australia, United States · 7 sites
Registry update: 2 Jun 2026
NCT07225387
Recruiting
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
Phase 4 · United States · 7 sites
Registry update: 6 Nov 2025
NCT07636044
Recruiting
Reduced Vaccine Response to HZ/su in SLE
Not applicable · South Korea · 1 site
Registry update: 9 Jun 2026
NCT06804057
Recruiting
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
Not applicable · United States · 1 site
Registry update: 6 Feb 2026
NCT06217107
Recruiting
Wellness & Workforce Solution for Lupus/Lupus Nephritis
Not applicable · United States · 1 site
Registry update: 24 Jul 2026
NCT06232304
Recruiting
Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
Not applicable · Canada, United States · 7 sites
Registry update: 30 Oct 2025
NCT06576271
Recruiting
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
Phase 1 · Argentina, Brazil, Spain, United Kingdom, Poland, United States · 28 sites
Registry update: 22 Jun 2026
Conflicting statuses (not updated in the registry for 4 months)
NCT07085676
Recruiting
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Phase 1 · Israel · 1 site
Registry update: 6 May 2026
NCT06189157
Recruiting
MB-CART19.1 in Refractory SLE
Phase 1/2 · Germany · 3 sites
Registry update: 26 Nov 2025

Ordered by registry start date. Freshness and sponsorship never change the order.